Identification of a peptide targeting CD56.

CD56 Antigen / antagonists & inhibitors Cell Surface Display Techniques Drug Discovery / methods Humans Immunoconjugates / pharmacology K562 Cells Leukocytes, Mononuclear / drug effects Peptide Library Peptides / chemistry Protein Binding
CD56 Cell isolation Diagnosis Natein Peptide

Journal

Immunobiology
ISSN: 1878-3279
Titre abrégé: Immunobiology
Pays: Netherlands
ID NLM: 8002742

Informations de publication

Date de publication:
07 2020
Historique:
received: 27 02 2020
revised: 14 06 2020
accepted: 04 07 2020
entrez: 5 8 2020
pubmed: 5 8 2020
medline: 6 8 2021
Statut: ppublish

Résumé

Neural cell adhesion molecule 1 (NCAM1/CD56) is expressed on immune cells, myoblasts, and malignant cells, and there is a growing demand for the genetic detection of CD56 and CD56-targeted therapy. In the present study, we developed a novel peptide ligand (designated Natein) that binds to human CD56 by using T7 phage display technology. Natein recognized the extracellular region of CD56 and could bind to natural killer (NK) cells and CD56-positive (CD56

Identifiants

DOI: 10.1016/j.imbio.2020.151982 PMID: 32747027
pubmed: 32747027
pii: S0171-2985(20)30097-8
doi: 10.1016/j.imbio.2020.151982
pii:
doi:

Substances chimiques

CD56 Antigen 0
Immunoconjugates 0
Peptide Library 0
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

151982

Informations de copyright

Copyright © 2020 Elsevier GmbH. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest We declare that all authors have seen and approved the final version of the manuscript being submitted. We warrant that the article is the authors' original work, hasn't received prior publication and isn't under consideration for publication elsewhere. We declare that we have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing of this paper.

Auteurs

Hongxing Huang (H)

MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, PR China.

Ying Liu (Y)

MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, PR China.

Xiaoming Ouyang (X)

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, PR China.

Hua Wang (H)

Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, PR China. Electronic address: wanghua9@mail.sysu.edu.cn.

Yan Zhang (Y)

MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, PR China. Electronic address: zhang39@mail.sysu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Antigènes CD56 › Identification of a peptide targeting CD56.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Ingénierie des protéines › Techniques d'exposition à la surface cellulaire › Identification of a peptide targeting CD56.
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Identification of a peptide targeting CD56.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Identification of a peptide targeting CD56.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › Identification of a peptide targeting CD56.
questionsmedicales.fr › Cellules › Cellules érythroïdes › Cellules K562 › Identification of a peptide targeting CD56.
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Identification of a peptide targeting CD56.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Banque de gènes › Banque de peptides › Identification of a peptide targeting CD56.
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Identification of a peptide targeting CD56.
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Identification of a peptide targeting CD56.